Arovella Therapeutics Ltd has released a press release.
Response to ASX Query regarding Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Manaing Director and CEO Resignation
- ArTiMist Appeal Lodged With TGA
- ZolpiMist Clinical Results Published
- European Anagrelide Cancer Patent
- Supplementary Prospectus
Later from Arovella Therapeutics
- SUDA Finalises Agreement With Cann Pharmaceutical
- Case For Share Consolidation and Appendix 3A.3
- SUDA Appoints Dr Michael Baker CEO
- SUDA Signs Co-Development Deal With Ordesa
- SANOFI and SUDA Entered Into A Feasibility Agreement
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics